Raw Material Hydroxychloroquine Sulfate Pharmaceutical Hydroxychloroquine Sulfate Powder Hydroxychloroquine Sulfate

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >98%
• Model NO.: D-sung Hydroxychloroquine sulfate
• Shelf Life: 2 Years
• Mf: C18h28cln3o5s
• MW: 433.95000
• Psa: 131.37000
• Logp: 4.28400
• Mdl: Mfcd00078203
• Boiling Point: 516.7ºC at 760 Mmhg
• Melting Point: 240 °c
• Flash Point: 266.3ºC
• Storage Condition: Store in a Cool
• Water Solubility: Soluble
• Rtecssafety Instructions: 37/39-26
• Rtecs: Kk3342500
• Customs Code: 2933499090
• Danger Sign: Ghs07
• Transport Package: Negotiable
• Specification: 98%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Raw Material Hydroxychloroquine sulfate Pharmaceutical Hydroxychloroquine sulfate powder Hydroxychloroquine sulfate

Product Description

Product Details

Chemical Name	Hydroxychloroquine sulfate
Synonyms	2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol,sulfuric acid;
CAS No.	747-36-4
Molecular Formula	C18H28ClN3O5S
Molecular Weight	433.95000
PSA	131.37000
LogP	4.28400

Hydroxychloroquine sulfate, medicine, the main ingredient is 2-4-(7-chloro-4-quinolinyl)aminopentylethylamino-ethanol sulfate. It is a film-coated tablet, which appears white or off-white after removing the coating. For the treatment of discoid lupus erythematosus and systemic lupus erythematosus.

Application&Function

Application
Hydroxychloroquine sulfate is an antimalarial drug, which also has anti-inflammatory, immunomodulatory and anticoagulant effects. At present, hydroxychloroquine is mainly used in the clinical treatment of rheumatoid arthritis, juvenile chronic arthritis, discoid lupus erythematosus and systemic erythema Lupus, but the clinical onset is slower, and usually requires 2 to 4 months of Chemicalbook time. The pharmacological effect of this drug is not very clear. It may be related to stabilizing the lysosomal membrane, inhibiting the formation of prostaglandins, inhibiting the chemotaxis of polymorphonuclear cells and the effect of phagocytic cells, and may interfere with monocyte interleukin- 1. Formation and inhibition of neutrophil superoxide release.
 

Specification